D
Derek L. Stirewalt
Researcher at Fred Hutchinson Cancer Research Center
Publications - 112
Citations - 17324
Derek L. Stirewalt is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 42, co-authored 101 publications receiving 15718 citations. Previous affiliations of Derek L. Stirewalt include University of Washington Medical Center & University of Washington.
Papers
More filters
Journal ArticleDOI
Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.
TL;DR: The findings suggest that FLT3 ITDs can be used as molecular markers for MRD in patients with AML.
Journal ArticleDOI
Molecular targets in acute myelogenous leukemia.
TL;DR: Some of the signaling pathways that are aberrantly regulated in AML are examined, focusing on the tyrosine kinase/RAS/MAP kinase and JAK/STAT pathways.
Journal ArticleDOI
Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA.
Derek L. Stirewalt,Era L. Pogosova-Agadjanyan,Najma Khalid,Dan R Hare,Paula A. Ladne,Olga Sala-Torra,Lue Ping Zhao,Jerald P. Radich +7 more
TL;DR: A single-stranded linear amplification protocol that combines the reproducibility of in vitro transcription and the amplification robustness of polymerase chain reactions is developed, and it is suggested that SLAP is an excellent alternative to IVT-based amplification protocols when RNA is limited by small sample size.
Journal ArticleDOI
Identification of Radiation-Induced Expression Changes in Nonimmortalized Human T Cells
Era L. Pogosova-Agadjanyan,Wenhong Fan,George E. Georges,George E. Georges,Jeffrey L. Schwartz,Crystal M. Kepler,Hana Lee,Amanda L. Suchanek,Michelle R. Cronk,Ariel R. Brumbaugh,Julia H. Engel,Michi Yukawa,Lue P. Zhao,Shelly Heimfeld,Derek L. Stirewalt,Derek L. Stirewalt +15 more
TL;DR: It is suggested that RNA-based expression assays for a small subset of genes can be employed to develop clinical biodosimetry assays to be used in assessments of radiation exposure and toxicity.
Journal ArticleDOI
Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3 /ITD AML
TL;DR: expression profiling revealed that samples harboring high FLT3/ITD-ARs aberrantly expressed genes within the recombination/DNA repair pathway, and the development of CN-LOH at the FLT 3 locus likely represents a late genomic event that occurs after the acquisition of theFLT3 /ITD.